PT4168033T - Administração de antagonista de cebp-beta e processos para a sua utilização - Google Patents

Administração de antagonista de cebp-beta e processos para a sua utilização

Info

Publication number
PT4168033T
PT4168033T PT218289023T PT21828902T PT4168033T PT 4168033 T PT4168033 T PT 4168033T PT 218289023 T PT218289023 T PT 218289023T PT 21828902 T PT21828902 T PT 21828902T PT 4168033 T PT4168033 T PT 4168033T
Authority
PT
Portugal
Prior art keywords
cebp
management
processes
beta antagonist
antagonist
Prior art date
Application number
PT218289023T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Publication of PT4168033T publication Critical patent/PT4168033T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT218289023T 2020-06-21 2021-06-21 Administração de antagonista de cebp-beta e processos para a sua utilização PT4168033T (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063041989P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US202063041990P 2020-06-21 2020-06-21
US202063041991P 2020-06-21 2020-06-21
US202163172560P 2021-04-08 2021-04-08

Publications (1)

Publication Number Publication Date
PT4168033T true PT4168033T (pt) 2026-03-24

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
PT218289023T PT4168033T (pt) 2020-06-21 2021-06-21 Administração de antagonista de cebp-beta e processos para a sua utilização

Country Status (14)

Country Link
US (1) US20230218717A1 (https=)
EP (1) EP4168033B1 (https=)
JP (1) JP2023531683A (https=)
KR (1) KR20230027054A (https=)
CN (1) CN115768458A (https=)
AU (1) AU2021297172B2 (https=)
BR (1) BR112022025880A2 (https=)
CA (1) CA3180559A1 (https=)
FI (1) FI4168033T3 (https=)
IL (1) IL299104A (https=)
MX (1) MX2022016478A (https=)
NZ (1) NZ795026A (https=)
PT (1) PT4168033T (https=)
WO (1) WO2021262604A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025532391A (ja) * 2022-10-07 2025-09-29 サピエンス・セラピューティクス・インコーポレーテッド Ｃ／ｅｂｐ－ベータアンタゴニスト及び免疫調節剤の使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
AU2024252321A1 (en) * 2023-04-13 2025-10-16 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516669A (ja) * 2013-02-22 2016-06-09 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 転写因子ａｔｆ５の阻害により腫瘍細胞を阻害するための組成物および方法
US10899834B2 (en) * 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
WO2018152446A2 (en) * 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
WO2019136125A1 (en) * 2018-01-03 2019-07-11 Sapience Therapeutics, Inc. Atf5 peptide variants and uses thereof
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Also Published As

Publication number Publication date
WO2021262604A3 (en) 2022-02-17
CN115768458A (zh) 2023-03-07
KR20230027054A (ko) 2023-02-27
FI4168033T3 (fi) 2026-04-07
JP2023531683A (ja) 2023-07-25
BR112022025880A2 (pt) 2023-01-10
EP4168033B1 (en) 2026-02-25
US20230218717A1 (en) 2023-07-13
EP4168033A2 (en) 2023-04-26
AU2021297172A1 (en) 2023-01-19
CA3180559A1 (en) 2021-12-30
AU2021297172B2 (en) 2025-01-30
EP4168033A4 (en) 2024-06-19
IL299104A (en) 2023-02-01
NZ795026A (en) 2026-03-27
MX2022016478A (es) 2023-02-01
WO2021262604A2 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
PT4168033T (pt) Administração de antagonista de cebp-beta e processos para a sua utilização
IL284837A (en) Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
IL280298A (en) Task completion using a blockchain network
PT3775091T (pt) Composições de fluoro-olefinas estabilizadas e métodos para a sua produção, armazenamento e utilização
EP3953832C0 (en) DATABASE MANAGEMENT SYSTEM
IL286278A (en) System and method for managing a use of a substance delivery device and a substance delivery device
PT3411358T (pt) Composto de piperidina substituído e a sua utilização
EP3919484A4 (en) HEXON GLUCOKINASE INHIBITOR AND ITS USES
EP4135591C0 (en) REUSABLE PUSH-ACTIVATED INTRAOSSEOUS ACCESS DEVICE
HUE065501T2 (hu) A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok
EP3779677A4 (en) SOFTWARE MANAGEMENT DEVICE
EP4165904C0 (en) ACCESS TRAFFIC MANAGEMENT
EP4518403A4 (en) METHOD AND APPARATUS FOR INTENTION MANAGEMENT
EP4305891A4 (en) TIME ALIGNMENT MANAGEMENT
EP4317153A4 (en) Abhd6 antagonist
EP3843984A4 (en) AUGER CONVEYOR AND TUBE FOR USE IN AN AUGER CONVEYOR
EP4050551A4 (en) WORK INFORMATION MANAGEMENT DEVICE AND WORK INFORMATION MANAGEMENT SYSTEM
EP4102320A4 (en) Management system
EP4393838C0 (en) SCREW-ON CAP FOR CONTAINERS AND CONTAINER EQUIPPED WITH SAID CAP
EP3946176C0 (en) WASTE MANAGEMENT DEVICE
KR102155793B9 (ko) 크라우드소싱 기반 프로젝트의 작업단가 관리 방법 및 장치
EP4060530A4 (en) DATA MANAGEMENT METHOD AND DEVICE
EP3748219C0 (en) APPARATUS FOR A GAS MANAGEMENT INSTALLATION
EP3975883A4 (en) Adapter for a surgical access device
EP4475601A4 (en) MBSR MANAGEMENT PROCESS